BR0011880A - Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica - Google Patents

Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica

Info

Publication number
BR0011880A
BR0011880A BR0011880-0A BR0011880A BR0011880A BR 0011880 A BR0011880 A BR 0011880A BR 0011880 A BR0011880 A BR 0011880A BR 0011880 A BR0011880 A BR 0011880A
Authority
BR
Brazil
Prior art keywords
compound
treatment
obesity
conditions associated
pharmaceutical composition
Prior art date
Application number
BR0011880-0A
Other languages
English (en)
Inventor
David John Heal
Original Assignee
Knoll Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Gmbh filed Critical Knoll Gmbh
Publication of BR0011880A publication Critical patent/BR0011880A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MéTODO PARA O TRATAMENTO DE CONDIçõES CO-MóRBIDAS ASSOCIADAS COM OBESIDADE, COMPOSTO , PRODUTO, USO DE UM COMPOSTO, E, COMPOSIçãO FARMACêUTICA". Método para o tratamento de condições co-mórbidas associadas com obesidade em humanos necessitados de tal tratamento que compreende administração ao humano de quantidade terapeuticamente efetiva do composto de fórmula (I): que inclui enanciómeros e sais farmaceuticamente aceitáveis dos mesmos, em que R~ 1~ e R~ 2~ são independentemente H ou metila, e quantidade terapeuticamente efetiva do composto de fórmula (II) em que o composto de fórmula (I) e o composto de fórmula (II): são administrados simultaneamente, separadamente ou seq³encialmente.
BR0011880-0A 1999-06-24 2000-06-16 Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica BR0011880A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9914744.9A GB9914744D0 (en) 1999-06-24 1999-06-24 Therapeutic agents
PCT/EP2000/005542 WO2001000205A1 (en) 1999-06-24 2000-06-16 Pharmaceutical composition containing sibutramine and orlistat

Publications (1)

Publication Number Publication Date
BR0011880A true BR0011880A (pt) 2002-03-19

Family

ID=10855955

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0011880-0A BR0011880A (pt) 1999-06-24 2000-06-16 Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica

Country Status (21)

Country Link
EP (1) EP1187606A1 (pt)
JP (1) JP2003503349A (pt)
KR (1) KR20020015357A (pt)
CN (1) CN1358092A (pt)
AU (1) AU5533200A (pt)
BG (1) BG106180A (pt)
BR (1) BR0011880A (pt)
CA (1) CA2375972A1 (pt)
CZ (1) CZ20014613A3 (pt)
GB (1) GB9914744D0 (pt)
HK (1) HK1049278A1 (pt)
HU (1) HUP0201878A3 (pt)
IL (1) IL147079A0 (pt)
MX (1) MXPA01012936A (pt)
NO (1) NO20016224L (pt)
PL (1) PL352402A1 (pt)
RU (1) RU2229289C2 (pt)
SK (1) SK18242001A3 (pt)
TR (1) TR200103699T2 (pt)
WO (1) WO2001000205A1 (pt)
ZA (1) ZA200109989B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US20040214804A1 (en) * 2003-04-25 2004-10-28 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-obesity agent
EP1807063A2 (en) 2004-10-25 2007-07-18 Solvay Pharmaceuticals GmbH Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
AU2007296074B2 (en) 2006-09-15 2012-07-12 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
US20100099773A1 (en) * 2006-11-22 2010-04-22 Jae-Sun Kim Inclusion complex of sibutramine and beta-cyclodextrin
CN101890017A (zh) * 2009-05-22 2010-11-24 北京奥萨医药研究中心有限公司 含有西布曲明和他汀类降脂药物的药物组合物及其用途
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
MX336980B (es) 2010-12-21 2016-02-09 Senosiain S A De C V Lab Combinacion y composicion para el tratamiento de obesidad.
UA114807C2 (uk) 2011-12-30 2017-08-10 Ревіва Фармасьютікалс, Інк. Композиції, синтез і способи застосування похідних фенілциклоалкілметиламіну

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727131D0 (en) * 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
CZ20014613A3 (cs) 2003-04-16
GB9914744D0 (en) 1999-08-25
NO20016224D0 (no) 2001-12-19
NO20016224L (no) 2002-02-12
MXPA01012936A (es) 2004-04-21
TR200103699T2 (tr) 2002-04-22
PL352402A1 (en) 2003-08-25
ZA200109989B (en) 2003-02-26
CA2375972A1 (en) 2001-01-04
HUP0201878A3 (en) 2005-04-28
SK18242001A3 (sk) 2003-02-04
HK1049278A1 (zh) 2003-05-09
KR20020015357A (ko) 2002-02-27
IL147079A0 (en) 2002-08-14
CN1358092A (zh) 2002-07-10
WO2001000205A1 (en) 2001-01-04
RU2229289C2 (ru) 2004-05-27
HUP0201878A2 (hu) 2003-08-28
AU5533200A (en) 2001-01-31
JP2003503349A (ja) 2003-01-28
EP1187606A1 (en) 2002-03-20
BG106180A (en) 2002-08-30

Similar Documents

Publication Publication Date Title
BR0315337A (pt) Composto, formulação farmacêutica, e, método para tratar câncer
BR0012590A (pt) Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central
EP1428821A8 (en) Piperidin-4-yl amines with analgesic effect
GEP20043324B (en) Purine Derivatives
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
MY119403A (en) Novel compounds with analgesic effect.
BR0113496A (pt) Composto ou um sal farmaceuticamente aceitável ou ester hidrolisável in vivo deste, uso destes, método para produzir um efeito inibidor do ciclo celular (anti-proliferação celular) em um animal de sangue quente, e, composição farmacêutica
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
DK0503440T3 (da) Sumatriptanholdige lægemidler
GEP20002298B (en) Benzimidazole Derivatives, Method of Their Production, Pharmaceutical Composition Containing the Same and Method for Its Treatment
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
BR0010938A (pt) Derivados da 13-metil eritromicina
SE9900961D0 (sv) Novel compounds
BR9814498A (pt) Processo para o tratamento de obesidade em um humano necessitando de tal tratamento, composto, uso do mesmo, produto, e, composição farmacêutica
BR9813319A (pt) Composto, composição farmacêutica para tratamento de infecções bacterianas, e, processos para tratar infecções bacterianas e para preparar um composto
BR9915480A (pt) Azalìdeos de 13 membros e a sua utilização como agentes antibióticos
BR0012610A (pt) Novo derivado de difenilpiperidina
BR0011880A (pt) Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica
BR0007452A (pt) Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
BR0011884A (pt) Método de tratamento da obesidade e condições comórbidas em um ser humano necessitando de tal tratamento, composto da fórmula i, produto contendo o composto da fórmula i, uso do composto da fórmula i, e, composição farmacêutica
GEP20043231B (en) Resorcinol Composition
AP9801235A0 (en) Erythromycin derivatives.

Legal Events

Date Code Title Description
PC Transfer

Owner name: ABBOTT GMBH & CO. KG (DE)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled
B25A Requested transfer of rights approved

Free format text: ABBOTT GMBH (DE)

B25D Requested change of name of applicant approved
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.